--- title: Optimizing NF1 Tumor Management Across the Lifespan Integrating Pain and QoL Assessment into MEK Inhibitor and Surgical Decision-Making description: Discover strategies to integrate pain and quality-of-life assessments, MEK inhibitors, and surgery across the NF1-PN lifespan. image: https://info.ceconcepts.com/hubfs/MM-170_MedEd2026-Featured.png --- [![CE Concepts Healthcare Education](https://info.ceconcepts.com/hs-fs/hubfs/CEC/_Brand%20Assets/CEC-Logo_Horizontal_Color_500x140.png?width=500&height=140&name=CEC-Logo_Horizontal_Color_500x140.png "CE Concepts Healthcare Education")](http://ceconcepts.com) ![MM-170\_MedEd2026-Featured](https://info.ceconcepts.com/hs-fs/hubfs/MM-170_MedEd2026-Featured.png?width=1200&height=800&name=MM-170_MedEd2026-Featured.png "MM-170_MedEd2026-Featured") #### Livestream ## Optimizing NF1 Tumor Management Across the Lifespan Integrating Pain and Quality-of-Life Assessment into MEK Inhibitor and Surgical Decision-Making ### Activity Description Neurofibromatosis type 1 (NF1) is a rare, lifelong genetic condition that can predispose individuals to tumor development. Among these are NF1-associated plexiform neurofibromas (PNs), infiltrative tumors that can be difficult to treat surgically, cause significant pain, and profoundly impact quality of life. The emergence of MAPK/ERK kinase (MEK) inhibitors has reshaped the treatment landscape, creating new opportunities for proactive, systemic management of NF1-PN. Because NF1 is rare, however, many clinicians have limited familiarity with evolving diagnostic frameworks, treatment selection, and strategies for managing long-term treatment-related toxicities. At the same time, fragmented communication across multidisciplinary teams can make it difficult to address the complex, cross-specialty needs of patients. Targeted education can empower clinicians and care teams to strengthen interprofessional decision-making, enhance diagnostic precision, apply evidence-based therapies, and mitigate toxicity across both pediatric and adult populations living with NF1-PNs. In this CE Concepts livestream symposium, expert faculty will incorporate patient-reported pain and quality-of-life data into treatment decision-making for patients with NF1-associated plexiform neurofibromas. Learners will be shown how to assess evidence‑based strategies for integrating MEK inhibitor therapy with surgery in the multidisciplinary management of patients with NF1‑PNs. Faculty will discuss structured, evidence-based strategies to anticipate, monitor, and manage MEK inhibitor-related toxicities in patients with NF1-PNs while maintaining dose intensity and minimizing treatment discontinuation across pediatric and adult care settings. ##### CEC Livestream # November 13, 2026 ## 6:00 PM EST This activity offers CME credit for: - Jointly Accredited Provider - Physicians (ACCME) - American Nurses Credentialing Center - American Nurses Credentialing Center with ILNA - Physician Associates (AAPA) - ABIM MOC - MIPS Improvement Activity - Royal College MOC **Credit Expiration Date:** 1/13/2027 ### Register Today! ### Faculty ![faculty\_LobbousM](https://info.ceconcepts.com/hs-fs/hubfs/CEC/CEC%20MM-170/faculty_LobbousM.png?width=200&height=200&name=faculty_LobbousM.png "faculty_LobbousM") ##### Mina Lobbous MD, MSPH (Moderator) Staff Neuro-Oncologist, Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center Director of Clinical Research, Brain Tumor & Neuro-Oncology Center Program Director, Neuro-Oncology Fellowship Program Medical Director, Neurofibromatosis and Schwannomatosis Center Assistant Professor, Cleveland Clinic Lerner College of Medicine Cleveland, OH ![faculty\_ShuhaiberH](https://info.ceconcepts.com/hs-fs/hubfs/CEC/CEC%20MM-170/faculty_ShuhaiberH.png?width=200&height=200&name=faculty_ShuhaiberH.png "faculty_ShuhaiberH") ##### Hans H. Shuhaiber MD Associate Professor, Department of Neurology University of Florida (UF), College of Medicine Director, Neurofibromatosis (NF) Clinic UF Health Neuromedicine Hospital Gainesville, FL ![faculty\_SundbyT](https://info.ceconcepts.com/hs-fs/hubfs/CEC/CEC%20MM-170/faculty_SundbyT.png?width=200&height=200&name=faculty_SundbyT.png "faculty_SundbyT") ##### R. Taylor Sundby MD Moseley Scholar, Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Health Clinical Director, Nemour Neurofibromatosis Clinic Assistant Professor of Pediatrics, Thomas Jefferson University Principal Investigator, Cancer Interception and Tumor Evolution Lab Wilmington, DE ![faculty\_SuppiahS](https://info.ceconcepts.com/hs-fs/hubfs/CEC/CEC%20MM-170/faculty_SuppiahS.png?width=200&height=200&name=faculty_SuppiahS.png "faculty_SuppiahS") ##### Suganth Suppiah MD, PhD, FRCSC Assistant Professor, Department of Surgery University of Toronto Surgeon-Scientist, Division of Neurosurgery Toronto Western Hospital Toronto, ON Canada ### Learning Objectives At the conclusion of this activity, learners will be able to better: - Incorporate patient-reported pain and quality-of-life data into treatment decision-making for patients with NF1-associated plexiform neurofibromas - Assess evidence‑based strategies for integrating MEK inhibitor therapy with surgery in the multidisciplinary management of patients with NF1‑PNs - Apply structured, evidence-based strategies to anticipate, monitor, and manage MEK inhibitor-related toxicities in patients with NF1-PNs while maintaining dose intensity and minimizing treatment discontinuation across pediatric and adult care settings ### Financial Support This program is supported through independent educational grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc. ### Target Audience Pediatric and adult oncologists, neuro-oncologists, neurologists, neurosurgeons, medical geneticists, nurse practitioners (NPs), physician associates (PAs), registered nurses (RNs), and their interprofessional team members who treat and manage pediatric and adult patients with NF1 ### Credit Information ![JA\_Commendation\_Mark\_edit2-1](https://info.ceconcepts.com/hs-fs/hubfs/CEC/JA_Commendation_Mark_edit2-1.png?width=125&height=110&name=JA_Commendation_Mark_edit2-1.png) ###### Jointly Accredited Provider In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. ###### Physicians (ACCME) Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ###### American Nurses Credentialing Center This activity is designated for 1.25 contact hours. **Note to Nurse Practitioners:** The content of this CNE activity pertains to Pharmacology. ![ONCC-logo](https://info.ceconcepts.com/hubfs/CEC/_Brand%20Assets/ONCC-logo.svg) ###### American Nurses Credentialing Center with ILNA This activity is designated for 1.00 contact hours. The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: ###### OCN® - Psychosocial Dimensions of Care - Symptom Management, Palliative Care, Supportive Care - Treatment ###### CBCN® - Psychosocial Dimensions of Care - Treatment ###### CPHON® - Psychosocial Dimensions of Care - Care of the Pediatric Hematology and Oncology Patient - Symptom Management, Palliative Care, Supportive Care - Treatment ###### AOCNP® - Psychosocial Dimensions of Care - Symptom Management, Palliative Care, Supportive Care - Treatment ###### ROCN® - Treatment ###### ![aapa\_Cat1\_CME\_logo](https://info.ceconcepts.com/hs-fs/hubfs/aapa_Cat1_CME_logo.png?width=99&height=100&name=aapa_Cat1_CME_logo.png)Physician Assistants (AAPA) Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. ###### ![ABIM-MOC](https://info.ceconcepts.com/hs-fs/hubfs/CMEO/_Brand%20Assets/Cred%20Logos/ABIM-MOC.png?width=100&height=34&name=ABIM-MOC.png)ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. ###### ![accredit-CME4MIPS](https://info.ceconcepts.com/hs-fs/hubfs/CMEO/accredit-CME4MIPS.png?width=100&height=44&name=accredit-CME4MIPS.png)MIPS Improvement Activity Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA\_PSPA\_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. ###### ![accredit-royalMOC](https://info.ceconcepts.com/hs-fs/hubfs/accredit-royalMOC.webp?width=100&height=100&name=accredit-royalMOC.webp)Royal College MOC Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program. ### Disclosure Declaration It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations. ##### Faculty **Dr. Lobbous** reports the following financial relationships: Advisory Board: Alexion Pharmaceuticals, Inc.; Servier Pharmaceuticals; and SpringWorks Therapeutics, Inc. Speakers Bureau: Alexion Pharmaceuticals, Inc. and SpringWorks Therapeutics, Inc. **Dr. Sundby** reports no financial relationships to disclose. **Dr. Shuhaiber** reports the following financial relationships: Advisory Board: Alexion Pharmaceuticals, Inc. and Merck & Co., Inc./SpringWorks Therapeutics, Inc. Research Support: Institutional research support from Alexion Pharmaceuticals, Inc.; Merck & Co., Inc.; Recursion; and SpringWorks Therapeutics, Inc. **Dr. Suppiah** reports the following financial relationships: Advisory Board: Alexion Pharmaceuticals, Inc. ##### Peer Reviewers/Planning Committee The following individuals have no financial relationships to disclose: Alaa Bawaneh, MD, PhD (Peer Reviewer) Michael Franks, APRN, AGACNP-BC, FNP-BC Keshia Pitt, PhD (Planning Committee) David Modrak, PhD (Planning Committee) Leijah Petelka (Planning Committee) Andrea Perseghin, EdD (Planning Committee) Sandra Caballero, PharmD (Planning Committee) Sharon Tordoff (Planning Committee) *\*All identified conflicts of interest have been mitigated.* ##### Unlabeled Use Disclosure Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use. ### Obtaining Credit **Post-tests, credit request forms, and activity evaluations must be completed online** (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac. [Visit Here For More Information](https://www.ceconcepts.com/activity/livestream-optimizing-nf1-tumor-management-across-the-lifespan-integrating-pain-and-quality-of-life-assessment-into-mek-inhibitor-and-surgical-decision-making/) Copyright © 2026 CE Concepts. All Rights Reserved.